These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1882 related items for PubMed ID: 17585291

  • 21. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.
    Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, Fry AM.
    MMWR Recomm Rep; 2022 Aug 26; 71(1):1-28. PubMed ID: 36006864
    [Abstract] [Full Text] [Related]

  • 22. Review of recommendations of the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, on varicella vaccine.
    Holmes SJ.
    J Infect Dis; 1996 Nov 26; 174 Suppl 3():S342-4. PubMed ID: 8896543
    [Abstract] [Full Text] [Related]

  • 23. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.
    Deichmann KA, Ferrera G, Tran C, Thomas S, Eymin C, Baudin M.
    Vaccine; 2015 May 11; 33(20):2379-86. PubMed ID: 25765966
    [Abstract] [Full Text] [Related]

  • 24. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients.
    Kawano Y, Suzuki M, Kawada J, Kimura H, Kamei H, Ohnishi Y, Ono Y, Uchida H, Ogura Y, Ito Y.
    Vaccine; 2015 Mar 17; 33(12):1440-5. PubMed ID: 25665961
    [Abstract] [Full Text] [Related]

  • 25. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR, Black S, Kuter BJ.
    J Infect Dis; 2008 Mar 01; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [Abstract] [Full Text] [Related]

  • 26. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH, Hirai HW, Tsoi KK.
    Expert Rev Vaccines; 2015 Mar 01; 14(8):1149-57. PubMed ID: 26081133
    [Abstract] [Full Text] [Related]

  • 27. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T, Baer M, Willems P.
    Pediatr Infect Dis J; 2007 Feb 01; 26(2):153-8. PubMed ID: 17259879
    [Abstract] [Full Text] [Related]

  • 28. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
    Marshall GS, Senders SD, Shepard J, Twiggs JD, Gardner J, Hille D, Hartzel J, Valenzuela R, Stek JE, Helmond FA.
    Hum Vaccin Immunother; 2016 Aug 02; 12(8):2188-2196. PubMed ID: 27149048
    [Abstract] [Full Text] [Related]

  • 29. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA, Svahn A, Rudén U, Bråkenhielm G, Storsaeter J, Akesson L, Linde A.
    Scand J Infect Dis; 2003 Aug 02; 35(10):736-42. PubMed ID: 14606613
    [Abstract] [Full Text] [Related]

  • 30. A new combination vaccine for measles, mumps, rubella and varicella.
    Zareba G.
    Drugs Today (Barc); 2006 May 02; 42(5):321-9. PubMed ID: 16801995
    [Abstract] [Full Text] [Related]

  • 31. Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children.
    Committee on Infectious Diseases.
    Pediatrics; 2011 Sep 02; 128(3):630-2. PubMed ID: 21873692
    [Abstract] [Full Text] [Related]

  • 32. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children.
    Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, Li S, Chan I, Heyse J, Waters M, Chan CY, Vessey SJ, Kaplan KM, Kuter BJ, Kaiser Permanente Medical Team for Varivax.
    Pediatr Infect Dis J; 2002 Jun 02; 21(6):555-61. PubMed ID: 12182381
    [Abstract] [Full Text] [Related]

  • 33. A combination vaccine against measles, mumps, rubella and varicella.
    Knuf M, Faber J, Barth I, Habermehl P.
    Drugs Today (Barc); 2008 Apr 02; 44(4):279-92. PubMed ID: 18536786
    [Abstract] [Full Text] [Related]

  • 34. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.
    Pediatr Infect Dis J; 2008 Aug 02; 27(8):724-30. PubMed ID: 18600190
    [Abstract] [Full Text] [Related]

  • 35. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM, LAIV Study Group.
    Pediatrics; 2008 Mar 02; 121(3):508-16. PubMed ID: 18310199
    [Abstract] [Full Text] [Related]

  • 36. Simultaneous administration of varicella vaccine and other recommended childhood vaccines--United States, 1995-1999.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2001 Nov 30; 50(47):1058-61. PubMed ID: 11808928
    [Abstract] [Full Text] [Related]

  • 37. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
    Vesikari T, Becker T, Gajdos V, Fiquet A, Thomas S, Richard P, Baudin M.
    Vaccine; 2012 Apr 26; 30(20):3082-9. PubMed ID: 22406278
    [Abstract] [Full Text] [Related]

  • 38. Early impact of universal varicella vaccination on childhood varicella and herpes zoster hospitalizations in Brazil.
    Scotta MC, Paternina-de la Ossa R, Lumertz MS, Jones MH, Mattiello R, Pinto LA.
    Vaccine; 2018 Jan 04; 36(2):280-284. PubMed ID: 29198917
    [Abstract] [Full Text] [Related]

  • 39. Assessing the introduction of universal varicella vaccination in the Netherlands.
    Boot HJ, de Melker HE, Stolk EA, de Wit GA, Kimman TG.
    Vaccine; 2006 Sep 11; 24(37-39):6288-99. PubMed ID: 16790302
    [Abstract] [Full Text] [Related]

  • 40. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix.
    Ouwens MJ, Littlewood KJ, Sauboin C, Téhard B, Denis F, Boëlle PY, Alain S.
    Clin Ther; 2015 Apr 01; 37(4):816-829.e10. PubMed ID: 25726457
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 95.